350 related articles for article (PubMed ID: 33232786)
1. TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.
Shih CT; Shiau CW; Chen YL; Chen LJ; Chao TI; Wang CY; Huang CY; Hung MH; Chen KF
Cancer Lett; 2021 Feb; 498():142-151. PubMed ID: 33232786
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy.
Lv Q; Yang H; Wang D; Zhou H; Wang J; Zhang Y; Wu D; Xie Y; Lv Y; Hu L; Wang J
J Med Chem; 2024 Apr; 67(8):6854-6879. PubMed ID: 38593344
[TBL] [Abstract][Full Text] [Related]
3. Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective.
Xiao Y; Zhang L; Zhu J; Zhang Y; Yang R; Yan J; Huang R; Zheng C; Xiao W; Huang C; Wang Y
Biomed Pharmacother; 2021 Nov; 143():112105. PubMed ID: 34560533
[TBL] [Abstract][Full Text] [Related]
4. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Chao TT; Wang CY; Lai CC; Chen YL; Tsai YT; Chen PT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
J Pharmacol Exp Ther; 2014 Nov; 351(2):352-8. PubMed ID: 25187431
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
[TBL] [Abstract][Full Text] [Related]
6. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
7. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
[No Abstract] [Full Text] [Related]
8. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
9. DPP Inhibition Enhances the Efficacy of PD-1 Blockade by Remodeling the Tumor Microenvironment in Lewis Lung Carcinoma Model.
Lei M; Liu J; Gao Y; Dai W; Huang H; Jiang Q; Liu Z
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672409
[TBL] [Abstract][Full Text] [Related]
10. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
11. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
[TBL] [Abstract][Full Text] [Related]
12. Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
Alhudaithi SS; Almuqbil RM; Zhang H; Bielski ER; Du W; Sunbul FS; Bos PD; da Rocha SRP
Mol Pharm; 2020 Dec; 17(12):4691-4703. PubMed ID: 33170724
[TBL] [Abstract][Full Text] [Related]
13. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
Cuccarese MF; Dubach JM; Pfirschke C; Engblom C; Garris C; Miller MA; Pittet MJ; Weissleder R
Nat Commun; 2017 Feb; 8():14293. PubMed ID: 28176769
[TBL] [Abstract][Full Text] [Related]
15. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
[TBL] [Abstract][Full Text] [Related]
16. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA.
Nie P; Hu W; Zhang T; Yang Y; Hou B; Zou Z
Cell Physiol Biochem; 2015; 35(6):2255-71. PubMed ID: 25895606
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer.
Zuo B; Li T; Liu X; Wang S; Cheng J; Liu X; Cui W; Shi H; Ling C
Clin Transl Oncol; 2023 Nov; 25(11):3188-3202. PubMed ID: 37115489
[TBL] [Abstract][Full Text] [Related]
19. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
20. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
